Discussion The direct factor Xa inhibitor rivaroxaban is an oral anticoagulant approved for
the prevention and treatment of venous thromboembolism and for stroke prophylaxis in …

Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous
thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an …

Rivaroxaban, a factor Xa inhibitor, is a new oral anticoagulant (NOAC) which has been
shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in patients with atrial …

Rivaroxaban is a direct factor Xa inhibitor approved for prevention of stroke, prevention and
treatment of venous thromboembolism and secondary prevention of acute coronary …

Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-
K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial …

Objectives: Identify the indications of rivaroxaban therapy. Describe the mechanism of action
of rivaroxaban. Outline the contraindications in a patient on rivaroxaban therapy. Review the …

Introduction: The increasing and widespread use of direct oral anticoagulants (DOACs)
demands guidelines and experts' consensus for their rational and safe use, especially in …

Rivaroxaban is the first agent available within a new class of anticoagulants called direct
factor X a inhibitors. Rivaroxaban is approved for use in the U nited S tates for the prevention …

Rivaroxaban, the first oral direct factor Xa inhibitor, was approved for stroke prevention in
nonvalvular atrial fibrillation in 2011. Limited data are available regarding major bleeding in …

Novel oral anticoagulants including the factor Xa inhibitor rivaroxaban are important
alternatives to warfarin for the prevention of thromboembolic stroke in patients with …